Epstein Secrets

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

opment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. EFTA00351823 OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

opment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to risk and retur

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

pment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to risk and retur